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ABSTRACT 
Inflammatory myofibroblastic tumor (IMT) is a rare benign tumor with an unknown origin. Its clinical 
and radiological manifestations are variable and non specific, also half of them are asymptomatic 
while cough, hemoptysis, dyspnea are possible to see. Therefore diagnosis is too hard to establish 
unless an exactly evaluation by an expert pathologist on a biopsy from surgical resection .The 
standard treatment for diagnostic and therapeutic reasons is a complete resection whereas 
incomplete resection increases the risk of recurrence. Here we report a 10-year old boy with 
prolonged cough and collapse-consolidation in his chest x-ray who referred to our pediatric center in 
north east of Iran. 
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CASE PRESENTATION   
A 10- year old boy referred from Nishabur in north east of Iran to our center in Dr.Sheikh pediatric 
hospital in Mashhad, Iran in January of 2015, who was suffering from chronic cough from one month 
ago without any response to medical treatment and he has had a history of choking 20 days ago. He 
had received variable antibiotic, mucolitics and a broad spectrum of anti cough drugs and he was 
admitted to a local hospital due to pneumonia that a segmental collapse in left lung was seen in his 
chest-x-ray. In past medical history he had a history of tonsillectomy his. His growth and 
developmental process was normal up to that time. In his family history he was the first child of a 
normal family and the second child was healthy up to now. His parents were relative. His 
grandmother has had asthma.  He had received common protocol of national vaccination in Iran.  
Therefore he was referred to our hospital for evaluating prolonged cough and collapse in left lung. In 
order to roll out of cystic fibrosis sweet test was done and normal results were obtained.  According 
to diagnostic evaluations also any immunodeficiency was not seen as his Cell Blood Count (CBC), 
Nitroblue tetrazolium (NBT) test were normal. In addition assessment of immunoglobulins such as 
IgE, IgA, IgM, IgG revealed normal values. Anti HIV antibody was negative. Complement rout 
evaluated by measurement of CH50 which was in normal range. Erythrocyte Sedimentation Rate 
(ESR) was a little high and non-quantitive C - reactive protein was negative. No organism was 
detected in blood cultures. Routine laboratory data like serum level of sodium, potassium, calcium, 
magnesium, phosphor and blood gas analysis, liver and renal function test also showed normal 
results. There was not any coagulopathies in our evaluations. 
 In chest imaging collapse and consolidations existed in left lung (figure3).  Mediastinal and lung CT 
scan with intravenous contrast injection revealed reduced volume of left lung and mediastinal and 
cardiac shift to left in addition to collapse-consolidation in whole left lung expect to apicoposterior 
segment in superior lobe. Mass like consolidation in left hill associated with enhancement had cut 
the left main bronchus. Adenopathy, plural and pericardial effusion were not seen .Soft tissue, chest 
wall, some cuts of upper abdomen were normal (figure3, 4).  
Finally diagnostic rigid bronchoscopy was performed particularly for roll out of foreign bodies or any 
other complications in his air ways. It was notable that there was a mass in left lung with a 
compression effect on left main bronchus. According to later thoracotomy, superior left lobectomy 
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(Sleeve surgery), left lung tumor were resected and some biopsies were sent to a professional 
pathologist who was specialist in pediatric tumors. A chest tube was inserted to left hemi thorax. 
The pathologist reported Inflammatory myofibroblastic tumor (inflammatory pseudotumor) as the 
definite diagnosis (figure1, 2). Results of immunohistochemical evaluation also approved the 
diagnosis of Inflammatory myofibroblastic tumor ( inflammatory pseudotumor ) as below: Actin : 
focally positive weakly ,desmin: negative  , synaptophysin : negative, chromogranin: negative. 
 
INTRODUCTION 
Inflammatory myofibroblastic tumor (IMT) is a rare benign tumor, accounting for 0.7% of all lung 
tumors (1). The frequency of this lesion in the lung is 0.04–1.0% among the general population (2). 
Its origin is unknown, but recent studies have shown that it is a true tumor rather than a reaction 
process (1). It should be considered when dealing with primary lung tumors in children, adolescents, 
and nonsmoking adults. It is, from a pathologic point of view, a benign tumor composed of a 
spindle cell proliferation and inflammatory cells, but, its clinical behavior, however, is variable with a 
benign evolution at one, and a malignant evolution with recurrent and metastatic disease at the 
other end of the spectrum (3). Therefore it is usually benign, although rare cases of malignant 
behavior have been reported (4). 
 
The first description of this tumor was given by Brunn in 1994((1, 5). In 1955, this tumor was given 
the name plasma cell granuloma by Lane et al. since plasma cells were predominant in the tumor (5). 
Thereafter many different terms were used to describe this tumor, the most common being 
inflammatory pseudotumor (5). Childhood inflammatory pseudotumor is the most common isolated 
lung lesion in children, usually is asymptomatic (4). 
 Inflammatory myofibroblastic tumor is defined by WHO as a myofibroblastic spindle cell soft tissue 
tumor with infiltrative plasma cells, lymphocytes, and eosinophils. It has been classified as an 
intermediate neoplasm in the current WHO histological typing of tumors of soft tissue and bone (5). 
Most of the reported cases are between 27 and 50 years of age, and under 40, no geographic or 
ethnic predisposition has been reported (2). It is predominantly seen in older children, without any 
sex predilection (1, 6). 
 
Its clinical and radiological manifestations are diverse and non specific. That’s why diagnosis is 
difficult to establish unless a surgical resection is performed (1). 
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Inflammatory myofibroblastic tumor has a number of pseudonyms. Some of them are inflammatory 
pseudotumor, plasma cell granuloma, fibroxanthoma, histiocytoma, sclerosing hemangioma, 
hyalinizing granuloma, etc (6).  
The other synonyms used were post inflammatory tumor, xanthofibroma, xanthogranuloma, 
fibrohistiocytoma, plasma cell granuloma, pseudosarcomatous myofibroblastic tumor, and invasive 
fibrous tumor of the tracheobronchial tree (5, 7). Inflammatory myofibroblastic tumor is now 
considered a more appropriate term as it takes into consideration the ultrastructural and 
immunohistochemical properties of this tumor (5). 
IMTs are benign solid tumors that arise in many anatomic sites. The lung is the most common site, 
but other sites are also reported, including the small and large bowel mesentery, mediastinum, 
retroperitoneum, omentum, spleen, spermatic cord, prostate, peripheral nerves, soft tissue, orbit 
and diaphragm (8). IMT is considered a benign tumor with local aggressive course but is not a 
malignancy in itself (8).  
Because of similar morphology of theses lesions, only immunohistochemical investigations allowed 
the correct final diagnoses. Histological examination was necessary for diagnosis (1). 
 
PATHOGENESIS 
There are many uncertainties about the pathogenesis of IMT. Several hypotheses have been 
proposed, most of which postulate an unchecked or exaggerated immunologic response of 
myofibroblasts  to a viral or foreign antigen-antibody reaction (6, 7). 
 Indeed, 30% of cases are closely related to recurrent respiratory infections which are caused by 
several microorganisms such as Mycoplasma, Nocardia, Actinomycetes (1). Also HHV-8 and EBV DNA 
sequences have been documented in some tumors indicating that viral infection may have some role 
in pathogenesis of this tumor (5). 
 
Other studies, however, suggest that it might be a true neoplasm due to the presence, at the 
myofibroblastic component, of a fusion gene involving the ALK gene, a tyrosine kinase oncogen 
located on chromosome 2p23, initially found to be arranged in anaplasic large cell lymphomas (1). 
This fusion leads to constitutive over expression of the ALK, causing cell proliferation (1). Coexistence 
of gene susceptibility and recurrent infection have also been reported (9). 
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CLINICAL MANIFESTATIONS 
 Approximately half of the patients are asymptomatic, whereas 26–56% of the patients have 
symptoms including cough, hemoptysis, dyspnea and chest pain (2). Nearly, 70% patients will be 
symptomatic with complains of fever, cough, dyspnea, and rarely hemoptysis (5). However, most 
patients are asymptomatic and the tumor is discovered incidentally on a chest X-ray performed for 
another reason. Weight loss and anorexia are rare (1). It was notable that chronic cough was the 
only symptom in our patient 
 
The presentation of IMT varies depending on the site and includes fever, weakness, abdominal pain, 
upper GI bleeding, weight loss, vomiting, poor appetite, gastroesophageal reflux, pallor, growth 
retardation and ascites. These symptoms can appear either alone or in a combination (8). Clubbing, 
and arthralgias may be noted. Generally no specific findings on physical or laboratory examinations 
exist (7). 
 
 
DIAGNOSIS  
Radiographic images and invasive diagnostic procedures, including bronchoscopy and percutaneous 
fine needle aspiration biopsy, are considered insufficient for diagnosis (7) as they may contain only 
inflammatory cells (9). Therefore, open lung biopsy or videothoracoscopic resection is often 
necessary (2). 
Consequently, surgery is crucial for both diagnostic and therapeutic reasons and frozen section 
histological examination is also subject to errors (7). Early diagnosis is crucial for the possibility of 
tissue-sparing treatment; most patients are diagnosed at an advanced stage (9). Only about 6% of 
patients are diagnosed on the basis of a biopsy specimen (9).  
 
 Radiological Assessment  
 CXR  
Radiological aspects are variable and nonspecific. Most patients (87%) have a mass or a 
pulmonary nodule, solitary, rarely multiple (5%), measuring 1 to 10 cm in diameter, sharply 
limited, smooth or bumpy. The lesion is located on the periphery with a predilection for the 
lower lobes (1, 6, 7). The mass lesion is discovered incidentally in chest x rays (2). 
 Multiple lung masses, pneumonic consolidation, atelectasis, hilar or mediastinal masses, 
pleural effusion, and cavitation are unusual (7). 
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CHEST CT SCAN  
Thoracic computed tomography reveals a single nodule and mass in 90% of these patients, 
and multiple nodules in 5%. Secondary infiltration of the hilus, mediastinum and airways 
were reported in 16% of the patients (2). It specifies the tissue or cystic nature of the tumor, 
its vascular behavior and it assesses the locoregional extension. Calcifications and cavitations 
are rare. Pleural effusion is seen in less than 10% and atelectasis in 8% of cases (1). Most 
inflammatory myofibroblastic tumors are well-circumscribed, nonencapsulated parenchymal 
masses, with less than 5% invading the mediastinum and chest wall (5). 
In a study a case of pulmonary IMT in a 15-year-old male with malignant features on 
radiographic and F-Fluoro-deoxyglucose positron emission tomography imaging was 
reported (3). 
Laboratory investigations  
Laboratory investigations are not specific. The most common finding is microcytic hypochromic 
anemia refractory to iron therapy (90.9%), but other laboratory findings, such as a high erythrocyte 
sedimentation rate, thrombocytosis, eosinophilia and hypergammaglobulinemia, may be seen (8). 
 
PATHOLOGY  
The pediatric primary pulmonary neoplasms represent a wide range of pathology from benign to 
malignant end of the spectrum. They are quite different in their histopathologic distribution from 
that of adults (6). 
However, in children, the major bulk of benign tumors consists inflammatory myofibroblastic 
tumors, chondromatous hamartomas, granular cell myoblastomas, leiomyomas, bronchial 
chondromas and teratomas (6), whereas the list of malignant lung tumors constitutes of  carcinoids, 
mucoepidermoid carcinomas, pleuropulmonary blastomas (PPBs), pulmonary blastomas (PBs), 
adenoid cystic carcinomas, sarcomas like fibrosarcomas, leiomyosarcomas, rhabdomyosarcomas (6). 
Gross description of inflammatory myofibroblastic tumors includes Solitary, small peripheral 
nodules, yellow, firm, covered by intact pleura or polypoid bronchial mass (4).The tumor is well 
circumscribed but not encapsulated, firm and homogeneous, with sometimes some foci of necrosis 
(1). 
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Macroscopically it is containing variable inflammation, haemorrhage, calcification, and rarely 
cavitation (7). 
Micro description includes Plasma cells (often abundant), lymphocytes, histiocytes and 
myofibroblasts. May have vascular proliferation, collagenous or hyalinized stroma, myxoid change, 
xanthoma cells, hemosiderin May resemble nodular fasciitis, fibrous histiocytoma or fibromatosis 
(4). Histologically there is fibrosis and intra-alveolar fibrosis, especially at the margin of the lesion (6). 
Inflammatory pseudotumours typically consists of variable amounts of stromal and cellular 
elements, with the myofibroblast, a cell involved in tissue repair, recognized as the principal cell-
type (7). In fact a lesion formed of varying proportions of spindle cells of myofibroblastic type, 
arranged in a fibrous, myxoid or calcified stroma, associated with an inflammatory component 
predominantly lymphocytic and plasmacytic, with a variable component of eosinophils (1). 
 
Because of the diversity of clinical and radiological manifestations of IMT, diagnosis is difficult to 
establish without chirurgical management (1).  
 
Pathological subtypes  
IMT includes three histological subtypes (1). 
• A richly vascularized and myxoïde resembling fasciitis or granulation tissue. 
• Onother is a more compact fascicular spindle cell proliferation with variable collagenized 
regions and lymphoid nodules, resembling fibromatosis 
• A very sclero-hyaline, slightly cellular pattern, looking more like a desmoid tumor (1). 
 
Another  different histologic patterns have been described (8). 
• Myofibroblasts have a spindle appearance and are distributed loosely in a myxoid stroma.  
• The second is more densely packed stromal cells intermingled with an inflammatory 
component.  
• The third is characterized by hyalinized, hypocellular stroma.   
These three patterns can be found in a single tumor intermixed closely . All of these features resolve 
after resection of the tumor (8). 
 
Matsubara et al (2) categorized inflammatory pseudotumor into three groups based on cellular types 
and main histologic properties: 
 A) Organized pneumonia formed by gradual healing of the intraalveolar exudation (44%), 
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 B) Fibrous histiocytoma formed by storiform proliferation of plasmocyte and lymphocyte 
aggregates (44%), and  
C) lymphoplasmocytic type formed by the aggregation of both plasmocyte and lymphocytes 
(12%)(2). 
Depending on the major histopathologic features, inflammatory pseudotumours are divided into the 
following types:fibrous histiocytoma, lymphoplasmacytic, and organising pneumonian (7). 
 
 
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry showed reactivity for vimentin and smooth muscle actin. 
Immunohistochemical positivity for anaplastic lymphoma kinase( ALK) is detectable in just over half 
of the cases with cytoplasmic staining, more rarely at the nuclear membrane ( 1). 
Immunohistochemistry has demonstrated the polyclonal nature of plasma cells with 
immunoglobulin G predominance (7). 
Some studies have suggested that IMT is a true neoplasm on the basis of characteristic gene 
alterations such as fusion of the gene encoding anaplastic lymphoma kinase (ALK) on chromosome 
2p23 and tropomyosin 3 (TPM3), which results in a functional chimeric protein (9). This 
phenomenon (TPM3-ALK) is detected in 30% of paediatric IMT cases (9). 
In a study (10) Anaplastic lymphoma kinase (ALK) expression was negative in all pulmonary samples 
by immunohistochemistry (IHC), however, rearrangement for ALK locus by fluorescence in situ 
hybridization was found in one lung and in two CNS samples. These findings may reflect higher 
sensitivity of the molecular biologic procedure compare to traditional IHC practice. In our pediatric 
experience, 25% of patients with lung IMT developed CNS lesions; therefore they consider that CNS 
screening in these patients should be considered, at diagnosis and later during follow up (10). 
The genetic landscape of this tumor is incompletely understood and therapeutic options are limited. 
Although 50% of IMTs harbor anaplastic lymphoma kinase (ALK) rearrangements, no therapeutic 
targets have been identified in ALK-negative tumors (11) .A study in 2014 reported for the first time 
that IMTs harbor other actionable targets, including ROS1 and PDGFRβ fusions. Molecular tumor 
profiling revealed a ROS1 fusion, and he had a dramatic response to the ROS1 inhibitor crizotinib 
(11). 
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PATHOLOGIC DIFFERENTIAL DIAGNOSIS 
 
Pathologic differential diagnosis includes organized pneumonia, lymphoma and solitary fibrous 
tumor. The mode of tumor growth, the low mitotic index, the polyclonality of lymphoid markers and 
the negativity of CD34 usually remove most of these diagnoses. Other differential diagnoses are 
desmoid fibromatosis, angiomyofibroblastoma, fibrosarcoma, leiomyoma, and malignant fibrous 
histiocytoma (1). 
Differentiating IMT from sarcoma may be challenging because of the local invasiveness of both 
pathologies. The lack of mitosis and nuclear atypia in IMT can differentiate it from sarcomas (12). 
The tumor mainly needs to be differentiated from lymphoma, plasmacytoma, organizing pneumonia 
and the rare malignant fibrous histiocytoma (6).  
 
 
TREATMENT  
The choice treatment for diagnostic and therapeutic reasons is a complete resection. An incomplete 
resection increases the risk of recurrence (1). While complete resection, wherever possible, is the 
standard therapy and results in excellent survival (4, 6). 
Wedge resection is adequate treatment if removal is complete. Lobectomy should be performed if it 
is required for complete resection and if the patient’s pulmonary reserve is adequate. Non-surgical 
treatment modalities including radiotherapy, chemotherapy, and corticosteroids may have a place in 
the setting of incomplete surgical resection, multifocal disease, postoperative tumour recurrence, or 
contra-indications to lung resection (7). Although spontaneous regression may occur, local 
expansion may cause significant morbidity and occasional death (7). 
 
Controversy still exists regarding the role of chemotherapy in IMT patients. According to Kovach et 
al., chemotherapy has been reserved for patients for whom resection is neither complete nor 
possible. The dosage and regimen of chemotherapy should be adjusted according to the biologic 
aggressiveness of the tumor, and there is no good evidence to support chemotherapy after 
complete resection regardless of tumor biology (13). Chemotherapy is useful in cases of multifocal, 
invasive lesions or in cases of local recurrence (1). 
Radiation, steroids and non steroidal anti inflammatory drugs have been used to treat inflammatory 
myofibroblastic tumors with variable and inconsistent results. Hence, surgical excision still remains 
the treatment of choice (5). 
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 Radiation treatment showed some benefit in pulmonary IMT .On the other hand, failure of radiation 
therapy in treating IMT has been reported, confirming surgical excision to be the treatment of 
choice(8). Radiation therapy is used in palliative treatment of this tumor, decreasing the mass effect 
of IMT and in patients whose tumors are not resectable (13). 
Corticosteroids are generally not useful in adults, although good results have been reported in 
children in cases of unresectable tumors or hilar and mediastinal invasion (1). The use of steroids is 
also recommended to reduce the inflammatory process that is surrounding the tumor, especially if 
the tumor is in the central nervous system (13). 
Using nonsteroidal antiinflammatory drugs as a conservative measure for treatment of patients with 
IMT whose tumors are not amenable to surgical resection (8).Of late, nonsteroidal anti-inflammatory 
drugs are being put to good use in large lesions (6). 
 
TUMOR BEHAVIOR AND RECURRENCE 
Most are parenchymal but some are endobronchial and may cause airway obstruction. Less than 5% 
invade the mediastinum and/or chest wall. Local recurrence is attributed to incomplete resection of 
the primary lesion (7). Metastasis of the tumor to mediastinum or the brain even many years after 
complete resection has been described. Rarely, simultaneous intra- and extrathoracic locations may 
occur. Association with other malignancies in sporadic cases has been reported (7) .Some 
of patients with lung IMT developed CNS lesions; therefore CNS screening in these patients should 
be considered, at diagnosis and later during follow up (10). 
About 18% to 40% of IMTs recur, and most recurrences appear in extrapulmonary lesions that are 
larger than 8 cm and are locally invasive .Retroperitoneal and mesenteric IMT seem to be associated 
with more frequent recurrences (8). Recurrence rates are 1.5% in tumors confined to the lung and 
46% in locally invasive tumors with extension beyond the lung (5). The frequency of recurrent 
disease is increased in cases with incomplete resection, larger tumours, deep location, presence of 
the susceptibility gene (ALK), and in younger patients (9). 
Recurrence is rare in cases with complete resection of the tumor (5). Long-term follow-up is 
recommended, especially in cases of incomplete resection since recurrence following incomplete 
resection has been reported (6) .Patients with recurrent disease should undergo re-resection (7). 
Based on an article in 2014 the recurrence rate after surgery ranges from 1.5 to 4%. Long-term 
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follow-up of patients after IMT resection is always required as recurrences have been reported 11 
years after primary tumour resection (9). 
Karnak et al reported a case with very high leukocyte count and suggest that this could be a good 
marker for recurrence (14). 
 
PROGNOSIS 
Despite IMT is a benign tumor, it is considered by some authors as a low grade tumor because of 
malignant features such as local invasiveness, recurrence (4% in cases of incomplete resection) or 
malignant transformation (exceptional). The evolution depends on the tumor size (less than or equal 
to 3 cm) and the quality of surgical resection. The 5-year survival is 91.3% (1). 
The prognosis of these rare tumours is excellent after complete surgical excision (7) .Five-year 
survival after resection exceeds 91% (9). 
 
CONCLUSION 
Inflammatory myofibroblastic tumor is a rare benign tumor (1) .The most common clinical picture is 
one of an asymptomatic, well-circumscribed lung mass that mimics cancer (7). Clinical and 
radiological presentation is variable and nonspecific (1). Clinicians need to bear in mind the diverse 
clinical presentations. Surgical excision is usually indicated to reach a firm diagnosis and cure (7). 
Only histological and immunohistochemical study can confirm the diagnosis. Despite being a benign 
lesion, its potential for recurrence and local invasion requires complete surgical resection (1). 
Because there is no "standard-of-care" therapy for IMT, the identification of actionable genomic 
alterations, in addition to ALK, is expected to redefine management strategies for patients with this 
disease (11). 
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Figure1: pathological picture of lung biopsy 
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Figure2: pathological picture of lung biopsy 
 
Figure3 :collapse consolidation in  chest x- Ray 
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Figure4 :Mass in chest CT scan 
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Figure5 :Mass in chest CT scan 
 
 
 
